Actemra actpen 162 MG/0.9 ML 0.9ML
Ended Awarded Last action
- Contract number
- SPE2DR26FM2LQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,003
Award facts
- Contract value 100% obligated
- $3,003.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 14, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $3,003.48 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order is scheduled for completion by January 15, 2026, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion vehicle extending through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company supplies a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Actemra, a biologic medication used to treat rheumatoid arthritis and other inflammatory conditions, exemplifies the company's role in fulfilling essential pharmaceutical needs for military treatment facilities and federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26FM2LQ?
SPE2DR26FM2LQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FM2LQ worth?
The government has obligated $3,003 on SPE2DR26FM2LQ.
Is contract SPE2DR26FM2LQ an order under another contract?
Yes. SPE2DR26FM2LQ is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM2LQ competed?
The extent of competition for SPE2DR26FM2LQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award